|
|
Profile
|
Delegates :
Keiji Nishiyama, PhD |
|
Incorporated :
July 1 , 2021 |
Paid in Capital :
100 Million yen |
Employees :
3 人 |
Address :
Mitsui Link Labo Shinkiba 1, Shinkiba 2-3-8, Koutou-ku, Tokyo TOKYO
〒136-0082
|
TEL/FAX :
81-3-5534-6133 / |
URL：
https://cellshoot.co.jp/ |
Attachment :
|
Mission/Background :
Cellshoot Therapeutics is a biotech start-up founded in July 2021 based on the intracellular protein network analysis and cell editing technologies developed by Dr. Masayuki Murata, a Specially Appointed Professor, and Dr. Fumi Kano, Associate Professor, at the Tokyo Institute of Technology.
The company develops drug discovery businesses by fully utilizing its core technologies, the PLOM-CON Analysis Technology for visualizing intracellular protein networks, and the Semi-intact Cell Resealing Technology. |
|
Technology & Business
|
The PLOM-CON Analysis extracts ‘feature quantities’ such as quantity, quality, and localization of various proteins from immunofluorescent-stained cell images, and visualizes their correlations as a network diagram by analyzing the pattern of change of each feature quantity over time. This novel technology has led to the elucidation of compounds’ mechanisms of action and the analysis of protein interactions behind them.
The Semi-intact Cell Resealing Technology can open pores in the cell membrane to permeate non-permeable materials into the cell, or replace the cytoplasm with that derived from another cell, and then close (reseal) the pores.
These technologies have huge potential to help solve drug discovery challenges and improve the success rate of drug discovery and development.
We will implement our technologies through contract and own drug discovery businesses, joint discovery projects, and out-licensing of clinical candidates. We are seeking strong partners to share and realize our vision.
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
Discovery Support
|
Discovery
|
We conduct target analyses, biomarker searching, hypothesis verification at the cellular level, etc. upon request.
|
To acquire new customers and cases to accumulate know-how, improve technologies, and raise awareness of the company.
|
In-house Discovery
|
Discovery
|
We conduct unique drug discovery programs based on our core technologies, which we expect to out-license.
|
To obtain lead compounds as soon as possible from our early projects currently underway or in preparation.
|
Joint Discovery
|
Discovery
|
We conduct joint projects with other drug discovery companies and out-license the candidates.
|
To establish a new alliance and initiate a joint program with a domestic or overseas company.
|
|
|
|
|
|
|
|
|
|
Highlights
|
In a recent project, we successfully identified the target molecule of a mechanism-unknown compound, and further elucidated another signaling pathway that modulates the compound’s action, demonstrating the power of our technology. We have also succeeded in expanding our findings by integrating our analysis with publicly available protein-protein interaction data. These advancements will be immediately reflected in our ongoing projects and applied to our drug discovery activities.
|
|
Hot news
|
As of April 2024, we are raising funds for further development of business. We will be happy to share more details upon inquiry. We are also recruiting motivated individuals who are willing to take on the challenge of creating new drugs.
|
|
Alliance strategy
|
Our PLOM-CON and Semi-intact Cell Resealing technologies are not only enabling tools but also revolutionary technologies that have the potential to dramatically improve clinical predictability and success rates in drug development. Their application can range from target discovery, efficacy and toxicity assessment, prediction of therapeutic response and resistance, translational research, and so on. We are proud to be flexible in the form of partnerships and look forward to receiving your inquiries.
|
|
|